Pancreatic Cancer Research

ResearcherColumbia University Irving Medical CenterActive in the last 2 years

Basil S. Bakir

Verified by OpenAlex author ID and NIH RePORTER profile ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5064061542; NIH RePORTER profile ID 10222837. Sources: OpenAlex.

Their work

Papers
9 (first author 2, last author 0)
Trials
0
Grants
1
Labs led
0
Collaborators
53
Papers, trials and grants by year

2016: 2 papers, 1 grant · 2017: none · 2018: 2 papers · 2019: none · 2020: none · 2021: 1 paper · 2022: none · 2023: 1 paper · 2024: 2 papers · 2025: 1 paper

Papers 9

  1. Cellular states associated with metastatic organotropism and survival in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41588-025-02345-5↗
  2. Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer. Co-author DOI 10.1038/s41586-024-07379-z↗
  3. Author Correction: Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer. Co-author DOI 10.1038/s41586-024-08084-7↗
  4. Phase Ib and Expansion Study of Gemcitabine, Nab-Paclitaxel, and Ficlatuzumab in Patients With Metastatic Pancreatic Cancer. Co-author DOI 10.1093/oncolo/oyad002↗
  5. PTHrP Drives Pancreatic Cancer Growth and Metastasis and Reveals a New Therapeutic Vulnerability. Co-author DOI 10.1158/2159-8290.cd-20-1098↗
  6. Regulation of Epithelial Plasticity Determines Metastatic Organotropism in Pancreatic Cancer. First author DOI 10.1016/j.devcel.2018.05.025↗
  7. Pancreas 3D Organoids: Current and Future Aspects as a Research Platform for Personalized Medicine in Pancreatic Cancer. First author DOI 10.1016/j.jcmgh.2017.12.004↗
  8. ETS-Transcription Factor ETV1 Regulates Stromal Expansion and Metastasis in Pancreatic Cancer. Co-author DOI 10.1053/j.gastro.2016.06.005↗
  9. Prrx1 isoform switching regulates pancreatic cancer invasion and metastatic colonization. Co-author DOI 10.1101/gad.263327.115↗

Grants 1

  1. The Role of p120ctn in Pancreatic Ductal Morphogenesis and Adenocarcinoma F30CA180601↗

Closest collaborators

The 25 strongest of 53 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Anil K. Rustgi · 5 shared papers, 2016–2023 · strength 0.43
  2. Jason Robert Pitarresi · 3 shared papers, 2018–2023 · strength 0.29
  3. Maximilian Reichert · 4 shared papers, 2016–2018 · strength 0.26
  4. Koushik K. Das · 3 shared papers, 2016–2023 · strength 0.23
  5. Shigetsugu Takano · 3 shared papers, 2016–2021 · strength 0.20
  6. Anirban Maitra · 3 shared papers, 2016–2021 · strength 0.20
  7. Michael S. May · 1 shared paper, 2025 · strength 0.18
  8. Alexander Grenander Raufi · 1 shared paper, 2025 · strength 0.18
  9. Morteza Chalabi Hajkarim · 1 shared paper, 2025 · strength 0.18
  10. Jacob K.R. Jamison · 1 shared paper, 2025 · strength 0.18
  11. Benjamin Izar · 1 shared paper, 2025 · strength 0.18
  12. Michael D. Kluger · 1 shared paper, 2025 · strength 0.18
  13. John A. Chabot · 1 shared paper, 2025 · strength 0.18
  14. Gulam Abbas Manji · 1 shared paper, 2025 · strength 0.18
  15. Leticia Moreira · 2 shared papers, 2018 · strength 0.16
  16. Kensuke Suzuki · 2 shared papers, 2018–2021 · strength 0.16
  17. Benoît Marchand · 2 shared papers, 2016–2021 · strength 0.15
  18. Douglas Adam Rubinson · 1 shared paper, 2023 · strength 0.13
  19. Srivatsan Raghavan · 1 shared paper, 2023 · strength 0.13
  20. Thomas Adam Abrams · 1 shared paper, 2023 · strength 0.13
  21. Lawrence Scott Blaszkowsky · 1 shared paper, 2023 · strength 0.13
  22. Andrew J. Aguirre · 1 shared paper, 2023 · strength 0.13
  23. Matthew B.B. Yurgelun · 1 shared paper, 2023 · strength 0.13
  24. Brian Matthew Wolpin · 1 shared paper, 2023 · strength 0.13
  25. Kimberly J. Perez · 1 shared paper, 2023 · strength 0.13

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.